Related Experiment Video
Updated: Jan 27, 2026
08:21
Curation of Computational Chemical Libraries Demonstrated with Alpha-Amino Acids
Published on: April 13, 2022
3.0K
Non-peptidic alpha(v)beta3 antagonists containing indol-1-yl propionic acids
Kristi Leonard1, Wenxi Pan, Beth Anaclerio
1Johnson & Johnson, Pharmaceutical Research and Development, L.L.C., 665, Stockton Drive, Exton, PA 19341, USA.
Bioorganic & Medicinal Chemistry Letters
|May 3, 2005
Summary
Researchers developed novel RGD mimetics, which are effective inhibitors of integrin alpha(v)beta3. These compounds show improved potency, offering new therapeutic possibilities for integrin-related conditions.
Area of Science:
- Medicinal Chemistry
- Biochemistry
- Pharmacology
Background:
- Integrin alpha(v)beta3 plays a crucial role in various physiological and pathological processes, including angiogenesis and tumor growth.
- RGD (Arginine-Glycine-Aspartic acid) sequences are known ligands for integrins, but their development as drugs is limited by stability and specificity.
- Developing small molecule mimetics of RGD can offer improved pharmacological properties.
Purpose of the Study:
- To synthesize and characterize novel RGD mimetics.
- To investigate the structure-activity relationship (SAR) of these compounds.
- To identify potent inhibitors of integrin alpha(v)beta3.
Main Methods:
- Synthesis of indol-1-yl propionic acid derivatives with diverse basic moieties and substitutions.
- In vitro evaluation of inhibitory activity against integrin alpha(v)beta3.
- Structure-activity relationship analysis to guide compound optimization.
Main Results:
- A series of novel RGD mimetics were successfully synthesized.
- Several compounds demonstrated potent inhibition of integrin alpha(v)beta3.
- SAR studies revealed key structural features contributing to enhanced potency.
Conclusions:
- The synthesized indol-1-yl propionic acid derivatives represent a promising class of RGD mimetics.
- These novel compounds exhibit potent inhibition of integrin alpha(v)beta3.
- Further development of these RGD mimetics could lead to new therapeutic agents targeting integrin-mediated diseases.
Related Concept Videos
02:43Peptide Bonds
82.6K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
82.6K
02:42Acidity of 1-Alkynes
11.1K
The acidic strength of hydrocarbons follows the order: Alkynes > Alkenes > Alkanes. The strength of an acid is commonly expressed in units of pKa — the lower the pKa, the stronger the acid. Among the hydrocarbons, terminal alkynes have lower pKa values and are, therefore, more acidic. For example, the pKa values for ethane, ethene, and acetylene are 51, 44, and 25, respectively, as shown here.
11.1K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
611
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
611
01:28Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists
970
Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...
970
01:24Cholinergic Antagonists: Pharmacokinetics
922
Cholinergic antagonists—such as antimuscarinics—are available in oral, topical, ocular, parenteral, and inhalational formulations. Most antimuscarinics are oral formulations, while scopolamine is available as a topical patch, and ipratropium and tiotropium are available as inhalation aerosols or powders. Atropine, tropicamide, and cyclopentolate are topically instilled in the eye. Most antimuscarinics are lipid-soluble and readily absorbed from the gastrointestinal tract and...
922
03:42Amino acids
104.9K
Amino acids are the monomers that comprise proteins. Each amino acid has the same fundamental structure, which consists of a central carbon atom, or the alpha (α) carbon, bonded to an amino group (NH2), a carboxyl group (COOH), and to a hydrogen atom. Every amino acid also has another atom or group of atoms bonded to the central atom known as the R group. There are 20 common amino acids present in proteins, each with a different R group. Variation in the amino acid sequence is responsible for...
104.9K